| Molecular formula | C204H301N51O64 |
|---|
| Molecular weight | 4492 g/mol |
|---|
| Registered trials | 61 |
|---|
| PubChem CID | 16130199 |
|---|
Regulatory status
Enfuvirtide is classified here as an unapproved research compound. No current FDA label data was available for this profile, so this page does not describe approved uses, dosing, or clinical benefit.
What enfuvirtide is
Enfuvirtide is a large synthetic peptide built from 36 amino acids, with a molecular formula of C204H301N51O64 and a molecular weight of about 4,492 daltons. Its structure is identified in PubChem under CID 16130199. No approved product label was found in the data reviewed for this profile, so no label-based mechanism or indication is presented here.
Trial footprint
Enfuvirtide has 61 registered trials. Sample records include a completed Phase 3 study examining use in patients with prior treatment and resistance across three anti-HIV drug classes, and a completed Phase 4 pilot study evaluating interruption of enfuvirtide in patients who had developed resistance to it. Another sample trial, a completed Phase 2 study, evaluated a combination antiretroviral regimen that included enfuvirtide as part of an optimized background therapy arm.
FAQ
This profile treats enfuvirtide as an unapproved research compound based on the data reviewed, which did not include an active FDA label. Readers should not assume approved status or approved use from this page.
Enfuvirtide is a synthetic peptide composed of 36 amino acids, with the molecular formula C204H301N51O64 and a molecular weight of roughly 4,492 daltons. It is cataloged in PubChem under CID 16130199.
There are 61 registered trials associated with enfuvirtide. Sample studies span Phase 2 through Phase 4 designs, including completed trials in treatment-experienced HIV patient populations.
Available sample trials include a completed Phase 3 study in patients with resistance across three anti-HIV drug classes, a completed Phase 4 pilot study on treatment interruption after resistance developed, and a completed Phase 2 study of a combination regimen.
No adverse event report data was available for enfuvirtide in the dataset used for this profile, so side effects are not summarized here.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem CID 16130199 ClinicalTrials.gov NCT00021554 NCT00187551 NCT00243230
Updated 2026-11-07